FDA Approves Daiichi’s Savaysa, But Not For AF Patients With Normal Kidney Function
This article was originally published in The Pink Sheet Daily
Executive Summary
The Japanese pharma scored an approval of its oral anticoagulant, but is at a disadvantage to competition due to a label that restricts use to patients with renal impairment.